MedTrace Logo

Sitagliptin in Type I Diabetic Patients

NCT01741103 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2022-03-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of sitagliptin on overall blood glucose concentrations in Type I Diabetic subjects. The study also aims to evaluate post meal glucagon concentrations in Type I Diabetic subjects (a possible mechanism of reduced blood glucose concentrations) and indices of oxidation stress in the plasma of these subjects.

Conditions

  • Diabetes Type I

Interventions

DRUG

sitagliptin

sitagliptin 100mg by mouth once a day for 12 weeks

DRUG

Placebo

Take one by mouth daily for 12 weeks

Sponsors & Collaborators

  • University at Buffalo

    lead OTHER

Principal Investigators

  • Paresh Dandona, MD · Kaleida Health and University at Buffalo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741103 on ClinicalTrials.gov